Australia markets open in 7 hours 9 minutes

  • ALL ORDS

    7,051.00
    +36.00 (+0.51%)
     

  • AUD/USD

    0.7757
    +0.0062 (+0.81%)
     

  • ASX 200

    6,770.40
    +27.80 (+0.41%)
     

  • OIL

    53.52
    +0.54 (+1.02%)
     

  • GOLD

    1,868.90
    +28.70 (+1.56%)
     

  • BTC-AUD

    44,609.41
    -253.00 (-0.56%)
     

  • CMC Crypto 200

    682.56
    -18.05 (-2.58%)
     
Sign up NOW ✉️:

Want to master your money in 2021?

Join Yahoo Finance's 6-week bootcamp challenge!

MHI Thermal Systems Receives 2020 "Agency for Natural Resources and Energy Commissioner's Award" for MSV2 Series of High-efficiency, Air-cooled Heat Pump Chillers

·3-min read

TOKYO, Jan 7, 2021 - (JCN Newswire) - Mitsubishi Heavy Industries Thermal Systems, Ltd. (MHI Thermal Systems), a part of Mitsubishi Heavy Industries (MHI) Group, has won an Agency for Natural Resources and Energy Commissioner's Award (Energy Savings Sector) in the "Product & Business Model" category at the 2020 Energy Conservation Grand Prize Awards sponsored by the Energy Conservation Center, Japan (ECCJ). This award was presented for the MSV2 series of air-cooled heat pump chillers(1) in recognition of its industry-leading coefficient of performance (COP)(Note2) achieved through a combination of the newly developed "e-3D scroll" compressor and other proprietary technologies. The awards ceremony will be held on January 27.





The MSV2 series comprises four models ranging from 40 to 70 horsepower (hp). These units incorporate the "e-3D scroll" compressor, a more advanced version of the "3D scroll" compressor that compresses the refrigerant from all directions. Modification to the scroll shape, from a step to a slope, has significantly reduced leakage loss, and provided a considerable gain in efficiency at low loads. In addition, the use of a large fan, long bell mouth, and small-diameter hairpin air heat exchanger provide 20% greater power efficiency compared to previous models. Further, this series offers approximately 55% energy reduction compared to absorption-type heating/cooling units.

The MSV2 series uses R32 refrigerant, which has around one-third the global warming potential (GWP)(3) of conventional R410A refrigerant. Along with a 28% reduction in refrigerant charge volume compared to previous models, and a 77% lower CO2 conversion factor, these units contribute to a lessening of the environmental load.

The ECCJ Energy Conservation Grand Prize Awards recognize outstanding energy-saving initiatives at businesses or workplaces that serve as examples for other companies, or outstanding energy-saving products and business models. The awards program was created to contribute to the realization of an energy-saving society by raising energy conservation awareness throughout Japan, and promoting the adoption of energy-saving products.

MHI Thermal Systems, encouraged by this award, will continue to develop technologies and products that provide further reductions in CO2 and energy savings. Further, by drawing on the collective technological capabilities realized through synergies generated from its broad business domain, including the thermal engineering business to enhance energy efficiency in a wide range of production plants, the large-scale refrigerator business for cooling large spaces, the air conditioning business to create a wide range of comfortable spaces, the transport refrigerating systems business essential to cold chains, and the automotive air-conditioning business, MHI Thermal Systems will focus on achieving optimal thermal solutions to meet the varied needs of customers.

(1) "Heat pump chiller" is a general term for a unit that creates and supplies hot and cold water for building air conditioning systems, or various types of industrial facilities. They are called "chillers" because they are used mainly in cooling applications, but the term "heat pump" is added because they can also be used to heat water to high temperatures. The internal system comprises refrigerant and water circulation systems, with heat exchanged as the refrigerant and water pass through a water heat exchanger.
(2) Coefficient of Performance (COP) is an indicator of the degree of efficiency that can be realized from using one kilowatt of electricity. Larger values indicate greater energy efficiency. For refrigeration systems, COP is the rated refrigeration capacity (kW) divided by electricity consumption (kW).
(3) Global Warming Potential (GWP) is a coefficient expressing a relative value, with CO2 fixed at a GWP of 1.0. Smaller values indicate greater environmental performance.

Copyright 2021 JCN Newswire. All rights reserved. www.jcnnewswire.com

Latest stories

  • Naf Naf Grill Signs Multi-Unit Deal in Dallas

    Naf Naf Grill signs multi-unit development agreement with INAA Restaurant Group in the Dallas-Fort Worth market.

  • China shuns imports of Aust copper ore

    China has shunned imports of Australian copper ores and concentrates amid rising tensions between the two nations, with imports in December falling to zero.

  • Google's advertising practices targeted by EU antitrust probe

    EU antitrust regulators have sought information from advertisers regarding Google's advertising technology practices, a European Commission document seen by Reuters shows. Alphabet-owned Google, the world's largest online search engine, has been hit with fines totalling 8.25 billion euros ($10 billion) in the last three years for blocking rivals in online shopping, Android smartphones and online advertising.

  • Djokovic hits back at his Open critics

    Novak Djokovic has made an impassioned defence of his comments on Australian Open quarantining, saying his "good intentions" have been misconstrued by critics.

  • Greybrook Realty Partners Invests $41,765,000 to Develop a Luxury High-Rise Condominium with Tribute Communities in Toronto, Ontario

    Development adds to the firm’s growing portfolio in and around Toronto’s Yorkville neighborhoodTORONTO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Greybrook Realty Partners Inc. announced today the successful closing of an equity investment by its managed issuer of $41,765,000 to acquire five properties located at 148, 152, 156 Avenue Road, 224 and 234 Davenport Avenue, in the City of Toronto and oversee the development of the assembled parcel of land. Together with its developer partner, Tribute Communities, the firm intends to develop the property into a luxury high-rise condominium residence consisting of over 380 units and more than 6,000 square feet of commercial space at grade. Located at the northwest corner of Avenue Road and Davenport Road, the development site offers excellent connectivity with four different TTC Subway stations in close proximity, nearby shops, restaurants, cafes and amenities in Yorkville’s upscale neighbourhood and along Bloor Street and Yonge Street. The site is also a short-walk from the University of Toronto’s St. George campus, the Royal Ontario Museum the Telus Centre for Performance and Learning and a number of galleries. The site is also close to several parks, including Ramsden Park, Dupont Parkette, and Robertson Davies Park. The property is one of several sites in the Bloor-Yorkville area in which Greybrook is actively developing, including the “Vertical Forest”, a unique residential development at Davenport Road and Bedford Road, intended to support over 350 tall trees on the exterior balconies of the building, and an ultra-luxury 29-storey mixed-use condominium building that will transform the corner of Yorkville Avenue and Avenue Road. “We are very excited to further participate in the growth and development of Yorkville and the surrounding area and we are thrilled to be partnering with our long-standing and well-respected developer partner, Tribute Communities, on this project,” noted Peter Politis, CEO, Greybrook Realty Partners. “Residential development sites such as this site have become much harder to find in the City of Toronto, particularly in the best neighbourhoods in the City. With the federal government’s planned increase in immigration over the next three years, Toronto will need new housing to support the growing population and transit-oriented developments such as this site will be in high demand.” About Greybrook Realty Partners Inc. Greybrook Realty Partners is a leading Toronto-based real estate private equity firm focused on investments in residential development and value-add assets. The firm offers investors the unique opportunity to partner with leading North American real estate developers and share in value creation activities. Greybrook Realty Partners, through its affiliates, has invested over $1.2 billion of equity in more than 80 real estate projects across Canada and the United States. In aggregate, its real estate investment portfolio is expected to result in the development of over 39 million square feet of residential and commercial density, with an estimated completion value of $17 billion. For more information, visit www.greybrook.com. Forward-Looking Information This news release contains forward-looking statements that are based on management’s current expectations and are subject to known and unknown uncertainties, which could cause actual results to differ from those contemplated or implied by such forward-looking statements. Greybrook is under no obligation to update or revise any forward-looking statements contained herein, whether as a result of new information, future events, or otherwise. For Further Information:Greybrook Realty Partners Inc.Sarah Mansour, Executive Director, Strategy & Corporate DevelopmentE: sarah.mansour@greybrook.comT: 416.322.9700 x551

  • Devon Energy Changes Time of Fourth-Quarter and Full-Year 2020 Earnings Call to 10AM ET

    OKLAHOMA CITY, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Devon Energy Corp. (NYSE: DVN) will host its fourth-quarter and full-year 2020 earnings conference call earlier than previously announced. The conference call will be held at 9 a.m. Central Time (10 a.m. Eastern Time) on Wednesday, Feb. 17. The call will consist primarily of answers to questions from analysts and investors. A webcast link to the conference call will be provided on Devon’s website at www.devonenergy.com. A replay will be available on the website following the call. As a reminder, the company will report its fourth-quarter and full-year 2020 results on Tuesday, Feb. 16, after the close of U.S. financial markets. The earnings release and accompanying presentation will be available on the company’s website at www.devonenergy.com. Devon Energy is a leading oil and gas producer in the U.S. with a premier multi-basin portfolio headlined by a world-class acreage position in the Delaware Basin. Devon’s disciplined cash-return business model is designed to achieve strong returns, generate free cash flow and return capital to shareholders, while focusing on safe and sustainable operations. For more information, please visit www.devonenergy.com. Investor Contacts Media ContactScott Coody, 405-552-4735Lisa Adams, 405-228-1732Chris Carr, 405-228-2496

  • Oil Rises With Focus on Stimulus and Market’s Firming Structure

    (Bloomberg) -- Oil climbed in sympathy with stronger equities as the likelihood of additional U.S. economic stimulus stoked optimism over a further boost to oil demand.Futures rose as much as 1.5% in New York on Wednesday. Investors are watching Washington, where Joe Biden is set to be sworn in as president, while also assessing Tuesday remarks from U.S. Treasury Secretary nominee Janet Yellen around a $1.9 trillion Covid-19 relief plan. The potential aid could support crude consumption ahead of wider vaccine distribution.In addition to stronger headline crude prices, the oil market’s structure has also firmed. U.S. crude’s closest contract is near the most expensive versus those for six months out in about a year. Key Brent spreads are also in what is known as backwardation, an indication of tight supply.Yellen’s call for lawmakers to “act big” on stimulus, has given people “the sense there’s a much better chance of a large stimulus,” said Michael Lynch, president of Strategic Energy & Economic Research. “It suggests you’re going to see demand recover faster and the economy more generally.”Traders have piled into oil this year, with output cuts from Saudi Arabia helping drive prices to the highest since February. Virus vaccines have boosted oil consumption and the global economy, while efforts to pass additional fiscal stimulus measures are seen helping to spur a further recovery. Still, the pandemic continues to be a risk with China locking down part of Beijing in the worst outbreak in months and Europe also reeling.“The demand destruction from increasingly frequent lockdowns is more than offset by Saudi’s unilateral cuts, which are fueling the tightening in market balances and in turn are associated with a tightening in crude oil’s term structure,” TD Securities commodity strategists including Bart Melek wrote in a note. “Price action is reflecting a declining supply outlook, which combined with fiery reflation signals, are providing powerful tailwinds.”As a way to gauge demand, rush-hour road congestion at 8 a.m. local time on Monday in both Shanghai and Beijing fell below typical 2019 levels for the first time since a public holiday in early October, according to TomTom, which collects car navigation data. In the U.K., gasoline and diesel sales in the week ended Jan. 10 were 45% and 32% lower, respectively, than the eight-week average before the country’s first lockdown in March.Meanwhile, Chinese imports of U.S. and Russian crude last month were at similar levels to November, while purchases from Saudi Arabia and Iraq fell, according to customs data released Wednesday. Imports from Iran almost doubled.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Hyliion Names Electrification Leader Bobby Cherian as Senior Vice President, Sales and Supply Chain

    Hyliion names electrification leader Bobby Cherian as senior vice president, sales and supply chain.

  • Waturu Holding A/S – resigned auditor sends subsidiary to compulsory dissolution

    Company annoucement nr. 51Fredericia, January 20. 2021 Waturu Holding A/S – resigned auditor sends subsidiary to compulsory dissolution The Waturu Holding Group is in the process of a change of auditor and in this connection the subsidiaryWaturu ApS has been sent for compulsory dissolution.The management will immediately ensure resumption through cooperation with the Danish BusinessAuthority.. About Waturu Holding A/S Waturu Holding A/S is a Greentech company, which develops innovative water technology for heating or treating water, with the focus on ensuring bacteria-free water and reducing water and energy consumption for heating hot water in properties and thus ensuring CO2 savings. Waturu Holding A/S is a major shareholder in the medical company Watgen Medical A/S and in the technology company Aquaturu A/S. Further information: CEO Toke Reedtz, cell.: +45 5188 1262, e-mail: toke@waturu.com Waturu Holding A/S Sjællandsgade 32 7100 Vejle Certified Adviser Tofte & Company ApS Christian IX Gade 7, 3 rd , 1111 København Phone.: +45 71961030 Contact: Sasja Dalgaard, mobile: +45 26100877, e-mail: sd@toftecompany.com Website: toftecompany.com Nasdaq First North Growth Market Important links:Websites: www.waturu.com Financial reports: www.waturu.com/documents Further press related news: www.linkedin.com/company/waturu/www.facebook.com/WaturuDenmark/

  • Global Neurosurgical Products Industry

    Global Neurosurgical Products Market to Reach $10. 6 Billion by 2027. Amid the COVID-19 crisis, the global market for Neurosurgical Products estimated at US$5. 5 Billion in the year 2020, is projected to reach a revised size of US$10.New York, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Neurosurgical Products Industry" - https://www.reportlinker.com/p05957505/?utm_source=GNW 6 Billion by 2027, growing at a CAGR of 10% over the analysis period 2020-2027. Embolization Products, one of the segments analyzed in the report, is projected to record a 10.8% CAGR and reach US$4.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Neurological Endoscopes segment is readjusted to a revised 10% CAGR for the next 7-year period. The U.S. Market is Estimated at $1.6 Billion, While China is Forecast to Grow at 9.3% CAGR The Neurosurgical Products market in the U.S. is estimated at US$1.6 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2027 trailing a CAGR of 9.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9.4% and 8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.9% CAGR. Stereo Tactic Radiosurgery Systems Segment to Record 9.3% CAGR In the global Stereo Tactic Radiosurgery Systems segment, USA, Canada, Japan, China and Europe will drive the 9.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$623.7 Million in the year 2020 will reach a projected size of US$1.2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.2 Billion by the year 2027.We bring years of research experience to this 6th edition of our report. The 182-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed. Competitors identified in this market include, among others, B. Braun Melsungen AGElekta ABIntegra LifeSciences Holdings CorporationJohnson & JohnsonKarl Storz GmbH & Co. KGMedtronic PLCPenumbra, Inc.Stryker CorporationTerumo CorporationVarian Medical Systems, Inc. Read the full report: https://www.reportlinker.com/p05957505/?utm_source=GNW I. INTRODUCTION, METHODOLOGY & REPORT SCOPE II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Global Competitor Market Shares Neurosurgical Products Competitor Market Share Scenario Worldwide (in %): 2019 & 2025 Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Neurosurgical Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 2: World Historic Review for Neurosurgical Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 3: World 15-Year Perspective for Neurosurgical Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 Table 4: World Current & Future Analysis for Embolization Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 5: World Historic Review for Embolization Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 6: World 15-Year Perspective for Embolization Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 7: World Current & Future Analysis for Neurological Endoscopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 8: World Historic Review for Neurological Endoscopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 9: World 15-Year Perspective for Neurological Endoscopes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 10: World Current & Future Analysis for Stereo Tactic Radiosurgery Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 11: World Historic Review for Stereo Tactic Radiosurgery Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 12: World 15-Year Perspective for Stereo Tactic Radiosurgery Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 13: World Current & Future Analysis for Aneurysm & AVM Clips by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 14: World Historic Review for Aneurysm & AVM Clips by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 15: World 15-Year Perspective for Aneurysm & AVM Clips by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 16: World Current & Future Analysis for Shunts by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 17: World Historic Review for Shunts by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 18: World 15-Year Perspective for Shunts by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 19: World Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 20: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 21: World 15-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 22: World Current & Future Analysis for Minimally invasive surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 23: World Historic Review for Minimally invasive surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 24: World 15-Year Perspective for Minimally invasive surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 25: World Current & Future Analysis for Open Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 26: World Historic Review for Open Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 27: World 15-Year Perspective for Open Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Market Facts & Figures US Neurosurgical Products Market Share (in %) by Company: 2019 & 2025 Market Analytics Table 28: USA Current & Future Analysis for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 29: USA Historic Review for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 30: USA 15-Year Perspective for Neurosurgical Products by Segment - Percentage Breakdown of Value Sales for Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments for the Years 2012, 2020 & 2027 Table 31: USA Current & Future Analysis for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 32: USA Historic Review for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 33: USA 15-Year Perspective for Neurosurgical Products by Procedure - Percentage Breakdown of Value Sales for Minimally invasive surgery and Open Surgery for the Years 2012, 2020 & 2027 CANADA Table 34: Canada Current & Future Analysis for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 35: Canada Historic Review for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 36: Canada 15-Year Perspective for Neurosurgical Products by Segment - Percentage Breakdown of Value Sales for Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments for the Years 2012, 2020 & 2027 Table 37: Canada Current & Future Analysis for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 38: Canada Historic Review for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 39: Canada 15-Year Perspective for Neurosurgical Products by Procedure - Percentage Breakdown of Value Sales for Minimally invasive surgery and Open Surgery for the Years 2012, 2020 & 2027 JAPAN Table 40: Japan Current & Future Analysis for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 41: Japan Historic Review for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 42: Japan 15-Year Perspective for Neurosurgical Products by Segment - Percentage Breakdown of Value Sales for Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments for the Years 2012, 2020 & 2027 Table 43: Japan Current & Future Analysis for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 44: Japan Historic Review for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 45: Japan 15-Year Perspective for Neurosurgical Products by Procedure - Percentage Breakdown of Value Sales for Minimally invasive surgery and Open Surgery for the Years 2012, 2020 & 2027 CHINA Table 46: China Current & Future Analysis for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 47: China Historic Review for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 48: China 15-Year Perspective for Neurosurgical Products by Segment - Percentage Breakdown of Value Sales for Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments for the Years 2012, 2020 & 2027 Table 49: China Current & Future Analysis for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 50: China Historic Review for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 51: China 15-Year Perspective for Neurosurgical Products by Procedure - Percentage Breakdown of Value Sales for Minimally invasive surgery and Open Surgery for the Years 2012, 2020 & 2027 EUROPE Market Facts & Figures European Neurosurgical Products Market: Competitor Market Share Scenario (in %) for 2019 & 2025 Market Analytics Table 52: Europe Current & Future Analysis for Neurosurgical Products by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 53: Europe Historic Review for Neurosurgical Products by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 54: Europe 15-Year Perspective for Neurosurgical Products by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 Table 55: Europe Current & Future Analysis for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 56: Europe Historic Review for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 57: Europe 15-Year Perspective for Neurosurgical Products by Segment - Percentage Breakdown of Value Sales for Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments for the Years 2012, 2020 & 2027 Table 58: Europe Current & Future Analysis for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 59: Europe Historic Review for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 60: Europe 15-Year Perspective for Neurosurgical Products by Procedure - Percentage Breakdown of Value Sales for Minimally invasive surgery and Open Surgery for the Years 2012, 2020 & 2027 FRANCE Table 61: France Current & Future Analysis for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 62: France Historic Review for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 63: France 15-Year Perspective for Neurosurgical Products by Segment - Percentage Breakdown of Value Sales for Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments for the Years 2012, 2020 & 2027 Table 64: France Current & Future Analysis for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 65: France Historic Review for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 66: France 15-Year Perspective for Neurosurgical Products by Procedure - Percentage Breakdown of Value Sales for Minimally invasive surgery and Open Surgery for the Years 2012, 2020 & 2027 GERMANY Table 67: Germany Current & Future Analysis for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 68: Germany Historic Review for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 69: Germany 15-Year Perspective for Neurosurgical Products by Segment - Percentage Breakdown of Value Sales for Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments for the Years 2012, 2020 & 2027 Table 70: Germany Current & Future Analysis for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 71: Germany Historic Review for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 72: Germany 15-Year Perspective for Neurosurgical Products by Procedure - Percentage Breakdown of Value Sales for Minimally invasive surgery and Open Surgery for the Years 2012, 2020 & 2027 ITALY Table 73: Italy Current & Future Analysis for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 74: Italy Historic Review for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 75: Italy 15-Year Perspective for Neurosurgical Products by Segment - Percentage Breakdown of Value Sales for Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments for the Years 2012, 2020 & 2027 Table 76: Italy Current & Future Analysis for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 77: Italy Historic Review for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 78: Italy 15-Year Perspective for Neurosurgical Products by Procedure - Percentage Breakdown of Value Sales for Minimally invasive surgery and Open Surgery for the Years 2012, 2020 & 2027 UNITED KINGDOM Table 79: UK Current & Future Analysis for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 80: UK Historic Review for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 81: UK 15-Year Perspective for Neurosurgical Products by Segment - Percentage Breakdown of Value Sales for Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments for the Years 2012, 2020 & 2027 Table 82: UK Current & Future Analysis for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 83: UK Historic Review for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 84: UK 15-Year Perspective for Neurosurgical Products by Procedure - Percentage Breakdown of Value Sales for Minimally invasive surgery and Open Surgery for the Years 2012, 2020 & 2027 REST OF EUROPE Table 85: Rest of Europe Current & Future Analysis for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 86: Rest of Europe Historic Review for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 87: Rest of Europe 15-Year Perspective for Neurosurgical Products by Segment - Percentage Breakdown of Value Sales for Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments for the Years 2012, 2020 & 2027 Table 88: Rest of Europe Current & Future Analysis for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 89: Rest of Europe Historic Review for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 90: Rest of Europe 15-Year Perspective for Neurosurgical Products by Procedure - Percentage Breakdown of Value Sales for Minimally invasive surgery and Open Surgery for the Years 2012, 2020 & 2027 ASIA-PACIFIC Table 91: Asia-Pacific Current & Future Analysis for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 92: Asia-Pacific Historic Review for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 93: Asia-Pacific 15-Year Perspective for Neurosurgical Products by Segment - Percentage Breakdown of Value Sales for Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments for the Years 2012, 2020 & 2027 Table 94: Asia-Pacific Current & Future Analysis for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 95: Asia-Pacific Historic Review for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 96: Asia-Pacific 15-Year Perspective for Neurosurgical Products by Procedure - Percentage Breakdown of Value Sales for Minimally invasive surgery and Open Surgery for the Years 2012, 2020 & 2027 REST OF WORLD Table 97: Rest of World Current & Future Analysis for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 98: Rest of World Historic Review for Neurosurgical Products by Segment - Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 99: Rest of World 15-Year Perspective for Neurosurgical Products by Segment - Percentage Breakdown of Value Sales for Embolization Products, Neurological Endoscopes, Stereo Tactic Radiosurgery Systems, Aneurysm & AVM Clips, Shunts and Other Segments for the Years 2012, 2020 & 2027 Table 100: Rest of World Current & Future Analysis for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery - Independent Analysis of Annual ¬Sales in US$ Million for the Years 2020 through 2027 Table 101: Rest of World Historic Review for Neurosurgical Products by Procedure - Minimally invasive surgery and Open Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 102: Rest of World 15-Year Perspective for Neurosurgical Products by Procedure - Percentage Breakdown of Value Sales for Minimally invasive surgery and Open Surgery for the Years 2012, 2020 & 2027 IV. COMPETITION Total Companies Profiled: 41Read the full report: https://www.reportlinker.com/p05957505/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

  • Stainless Steel Database 2021: Monthly Production and Trade for the Past 11 Years

    Dublin, Jan. 20, 2021 (GLOBE NEWSWIRE) -- The "Stainless Steel Database" database has been added to ResearchAndMarkets.com's offering. This dedicated database is an essential tool for the stainless steel specialist. The Stainless Steel Database consists of monthly production and trade for the past 11 years and is summarised by product and trading partner for the top 20 producing and top 20 consuming countries. Apparent consumption and summary trade data by country is also provided. Users can subscribe to either full or limited access to this database for 12 months through the publisher's website using unique login details. Limited Access subscribers receive access to the database only, under a Single-User Licence. Full Access subscribers will have a global Enterprise Licence with the benefit of unlimited users to the data across your corporation. Included with this subscription is the Annual Stainless Steel Statistics publication and Stainless Steel Long Term Series. For more information about this database visit https://www.researchandmarkets.com/r/iozc1j Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

  • United Arab Emirates Crude Oil Refinery Outlook, 2025: Total Refining Capacity, Crude Distillation Unit Capacity, Condensate Splitter Unit Capacity, Catalytic Cracking Capacity, Hydrocracking Capacity - ResearchAndMarkets.com

    The "United Arab Emirates Crude Oil Refinery Outlook to 2025" report has been added to ResearchAndMarkets.com's offering.

  • Covenant Completes Acquisition of One Advocate Group

    Covenant Multifamily Offices, LLC announced the successful completion of its acquisition of One Advocate Group, a financial planning & advisory firm.

  • Donald Trump pardons Casey Urlacher, brother of Bears great Brian Urlacher, in sports gambling case

    Bears great Brian Urlacher met with President Donald Trump in March 2020, which may have led to his brother Casey's pardon on illegal gambling charges.

  • US STOCKS-S&P 500, Nasdaq scale record highs as Netflix jumps; Biden takes office

    The S&P 500 and the Nasdaq hit all-time highs on Wednesday as Joe Biden prepared to take charge as U.S. President, while Netflix shares surged after saying it will no longer need to borrow billions of dollars to finance its TV shows and movies. Shares of the world's largest streaming service surged 14% to add more than $30 billion to its market capitalization, helping boost the broader tech-heavy Nasdaq 100 index.

  • BW Energy: Contemplated Private Placement

    CONTEMPLATED PRIVATE PLACEMENT NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF ANERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE "UNITED STATES"), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. BW Energy Limited (the “Company”) has engaged DNB Markets, a part of DNB Bank ASA and Pareto Securities AS (the “Managers”), to assist the Company in a contemplated private placement (the “Private Placement”) of new shares in the Company with gross proceeds of up to USD 75 million. The Private Placement is directed towards Norwegian investors and international institutional investors pursuant to and in compliance with applicable exemptions from relevant registration, filing and prospectus requirements, and subject to other applicable selling restrictions. The net proceeds from the Private Placement will be used for capital investments in the Dussafu licence in Gabon, development of the Maromba discovery in Brazil, new ventures and for other general corporate purposes. BW Energy CEO Carl Krogh Arnet comments; “We proved the resilience of our strategy and business model in 2020 with a swift and decisive response to the pandemic and oil price decline by scaling back investments while maintaining operational regularity and generating strong operational cash flow throughout the year. Carl Krogh Arnet continues; “We have a busy year ahead with planned production start from the last two Tortue phase 2 wells, drilling of a further Hibiscus exploration well and start of Hibiscus/Ruche field development including conversion of the first jack-up rig to a production platform. Our current asset portfolio offers significant growth potential, and we see an increasing number of attractive inorganic opportunities. Raising additional equity will strengthen our financial capacity, flexibility and ability to convert proven resources into highly profitable producing reserves.” The subscription price in the Private Placement will be determined by the Board of Directors or a subcommittee thereof (the "Board") based on an accelerated book-building process conducted by the Managers. The application period commences today on 20 January 2021 at 16:30 (CET) and will close on 21 January 2021 at 08:00 hours (CET). The Company, together with the Managers, reserves the right to close or extend the application period at any time at their sole discretion, at short notice. The minimum order size in the Private Placement is a NOK amount equivalent to EUR 100,000. The allocation of shares will be determined at the end of the book-building process. The final allocation will be made at the discretion of the Board in consultation with the Managers. No allocation will be made for amounts less than a NOK amount equivalent to EUR 100,000, other than in accordance with applicable exemptions from relevant prospectus requirements. BW Group Limited, which is the Company's second largest shareholder and represented on the Board, has pre-committed to subscribe for USD 26,347,169 in the Private Placement which is equal to their pro-rata share of the Company (35.13%). Carl Arnet, CEO of BW Energy, has pre-committed to subscribe for USD 770,245 which is equal to his pro-rata share of the Company (1.03%). The Board may allocate less than the pre-committed amount to BW Group Limited if deemed beneficial to the overall transaction, the free float of shares on the Oslo Stock Exchange and the shareholder structure of the Company. The completion of the Private Placement is conditional upon approval by the Board. Delivery of the new shares allocated in the Private Placement will, in order to facilitate delivery-versus-payment and timely delivery of already listed shares to subscribers in the Private Placement, be made by delivery of existing and unencumbered shares in the Company, pursuant to a share lending agreement entered into between the Company, the Managers and BW Group Limited. The borrowed shares will be redelivered by the Managers to BW Group Limited in the form of new shares in the Company to be issued in connection with the Private Placement. The Company has considered the Private Placement in light of the equal treatment obligations under the Norwegian Securities Trading Act and the rules on equal treatment under Oslo Rule Book II for companies listed on the Oslo Stock Exchange and the Oslo Stock Exchange's Guidelines on the rule of equal treatment, and the Board is of the opinion that the contemplated transaction is in compliance with these requirements and guidelines. Taking into consideration the time, costs and expected terms of alternative methods of the securing the desired funding, the Board has concluded that offering new shares in a private placement on acceptable terms at this time is in the common interest of the shareholders of the Company. The Company may, subject to completion of the Private Placement, and certain other conditions, resolve to carry out a subsequent offering of new shares which, subject to applicable securities law, will be directed towards existing shareholders in the Company as of 20 January 2021 (as registered in the VPS two trading days thereafter), who (i) were not included in the pre-sounding phase of the Private Placement, (ii) were not allocated Offer Shares in the Private Placement, and (iii) are not resident in a jurisdiction where such offering would be unlawful or, would (in jurisdictions other than Norway) require any prospectus, filing, registration or similar action. Advokatfirmaet Thommessen AS is acting as legal advisor to the Company in connection with the Private Placement and Advokatfirmaet Schjødt AS is acting as legal advisor to the Managers in connection with the Private Placement. For further information, please contact: Knut R. Sæthre, CFO BW Energy, +47 91 11 78 76ir@bwenergy.no About BW Energy:BW Energy is a growth E&P company with a differentiated strategy targeting proven offshore oil and gas reservoirs through low risk phased developments. The Company has access to existing FPSOs to reduce time to first oil and cashflow with lower investments than traditional offshore developments. The main assets are 73.5% of the producing Dussafu Marine Permit offshore Gabon and a 95% interest in the Maromba field in Brazil, both operated by the Company. Total net 2P+2C reserves were 247 million barrels at the start of 2021. Important Notices This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase, any securities of the Company. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and accordingly may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any part of the offering or its securities in the United States or to conduct a public offering of securities in the United States. Any sale in the United States of the securities mentioned in this announcement will be made solely to "qualified institutional buyers" as defined in Rule 144A under the Securities Act. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression "Prospectus Regulation" means Regulation 2017/1129 as amended together with any applicable implementing measures in any Member State. This communication is only being distributed to and is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only for relevant persons and will be engaged in only with relevant persons. Persons distributing this communication must satisfy themselves that it is lawful to do so. Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "strategy", "intends", "estimate", "will", "may", "continue", "should" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Actual events may differ significantly from any anticipated development due to a number of factors, including without limitation, changes in investment levels and need for the Company’s services, changes in the general economic, political and market conditions in the markets in which the Company operate, the Company’s ability to attract, retain and motivate qualified personnel, changes in the Company’s ability to engage in commercially acceptable acquisitions and strategic investments, and changes in laws and regulation and the potential impact of legal proceedings and actions. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not provide any guarantees that the assumptions underlying the forward-looking statements in this announcement are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this announcement or any obligation to update or revise the statements in this announcement to reflect subsequent events. You should not place undue reliance on the forward-looking statements in this document. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm, or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement. Neither of the Managers nor any of their respective affiliates makes any representation as to the accuracy or completeness of this announcement and none of them accepts any responsibility for the contents of this announcement or any matters referred to herein. This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities in the Company. Neither the Managers nor any of their respective affiliates accepts any liability arising from the use of this announcement. This information is subject of the disclosure requirements of section 5-12 of the Norwegian Securities Trading Act.

  • TREASURIES-Prices slip on new supply as Biden presidency begins

    The slide in Treasury prices pushed yields up, with the benchmark 10-year note trading at 1.100%. Biden was expected to sign the orders and memorandums in the Oval Office of the White House in the afternoon, making his first moves on the pandemic and climate change. Biden also will begin the process of re-entering the Paris climate accord and issue a sweeping order tackling climate change, including revoking the presidential permit granted to the disputed Keystone XL oil pipeline, aides said.

  • North America Foot Orthotic Insoles Market Forecast to 2027: Increasing Incidence of Diabetes, Arthritis, and Other Foot Conditions & Growing Demand from Sports Sector - ResearchAndMarkets.com

    The "North America Foot Orthotic Insoles Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product Type; Material, Gel, and Others; Application; Distribution Channel, and Country" report has been added to ResearchAndMarkets.com's offering.

  • Global Neurovascular Stents Industry

    Global Neurovascular Stents Market to Reach $2. 1 Billion by 2027. Amid the COVID-19 crisis, the global market for Neurovascular Stents estimated at US$919. 6 Million in the year 2020, is projected to reach a revised size of US$2.New York, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Neurovascular Stents Industry" - https://www.reportlinker.com/p05957507/?utm_source=GNW 1 Billion by 2027, growing at aCAGR of 12.3% over the period 2020-2027. Carotid Artery Stents, one of the segments analyzed in the report, is projected to record 12.8% CAGR and reach US$1.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Intracranial Stents segment is readjusted to a revised 11.1% CAGR for the next 7-year period. The U.S. Market is Estimated at $271.5 Million, While China is Forecast to Grow at 11.8% CAGR The Neurovascular Stents market in the U.S. is estimated at US$271.5 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$361.7 Million by the year 2027 trailing a CAGR of 11.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.9% and 10.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.9% CAGR.We bring years of research experience to this 9th edition of our report. The 171-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed. Competitors identified in this market include, among others, Abbott LaboratoriesACANDIS GmbHBlockade Medical LLCCordis CorporationInspireMD, Inc.Medtronic PLCMicroPort Scientific CorporationSTI Laser Industries, Ltd.Stryker CorporationTerumo Medical CorporationW. L. Gore & Associates Read the full report: https://www.reportlinker.com/p05957507/?utm_source=GNW I. INTRODUCTION, METHODOLOGY & REPORT SCOPE II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Global Competitor Market Shares Neurovascular Stents Competitor Market Share Scenario Worldwide (in %): 2019 & 2025 Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: Neurovascular Stents Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2020-2027 Table 2: Neurovascular Stents Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2012-2019 Table 3: Neurovascular Stents Market Share Shift across Key Geographies Worldwide: 2012 VS 2020 VS 2027 Table 4: Carotid Artery Stents (Product Type) World Market by Region/Country in US$ Thousand: 2020 to 2027 Table 5: Carotid Artery Stents (Product Type) Historic Market Analysis by Region/Country in US$ Thousand: 2012 to 2019 Table 6: Carotid Artery Stents (Product Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2012 VS 2020 VS 2027 Table 7: Intracranial Stents (Product Type) Potential Growth Markets Worldwide in US$ Thousand: 2020 to 2027 Table 8: Intracranial Stents (Product Type) Historic Market Perspective by Region/Country in US$ Thousand: 2012 to 2019 Table 9: Intracranial Stents (Product Type) Market Sales Breakdown by Region/Country in Percentage: 2012 VS 2020 VS 2027 Table 10: Hospitals (End-Use) Global Market Estimates & Forecasts in US$ Thousand by Region/Country: 2020-2027 Table 11: Hospitals (End-Use) Retrospective Demand Analysis in US$ Thousand by Region/Country: 2012-2019 Table 12: Hospitals (End-Use) Market Share Breakdown by Region/Country: 2012 VS 2020 VS 2027 Table 13: Ambulatory surgical centers (End-Use) Demand Potential Worldwide in US$ Thousand by Region/Country: 2020-2027 Table 14: Ambulatory surgical centers (End-Use) Historic Sales Analysis in US$ Thousand by Region/Country: 2012-2019 Table 15: Ambulatory surgical centers (End-Use) Share Breakdown Review by Region/Country: 2012 VS 2020 VS 2027 III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Market Facts & Figures US Neurovascular Stents Market Share (in %) by Company: 2019 & 2025 Market Analytics Table 16: United States Neurovascular Stents Market Estimates and Projections in US$ Thousand by Product Type: 2020 to 2027 Table 17: Neurovascular Stents Market in the United States by Product Type: A Historic Review in US$ Thousand for 2012-2019 Table 18: United States Neurovascular Stents Market Share Breakdown by Product Type: 2012 VS 2020 VS 2027 Table 19: United States Neurovascular Stents Latent Demand Forecasts in US$ Thousand by End-Use: 2020 to 2027 Table 20: Neurovascular Stents Historic Demand Patterns in the United States by End-Use in US$ Thousand for 2012-2019 Table 21: Neurovascular Stents Market Share Breakdown in the United States by End-Use: 2012 VS 2020 VS 2027 CANADA Table 22: Canadian Neurovascular Stents Market Estimates and Forecasts in US$ Thousand by Product Type: 2020 to 2027 Table 23: Canadian Neurovascular Stents Historic Market Review by Product Type in US$ Thousand: 2012-2019 Table 24: Neurovascular Stents Market in Canada: Percentage Share Breakdown of Sales by Product Type for 2012, 2020, and 2027 Table 25: Canadian Neurovascular Stents Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2020 to 2027 Table 26: Neurovascular Stents Market in Canada: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2012-2019 Table 27: Canadian Neurovascular Stents Market Share Analysis by End-Use: 2012 VS 2020 VS 2027 JAPAN Table 28: Japanese Market for Neurovascular Stents: Annual Sales Estimates and Projections in US$ Thousand by Product Type for the Period 2020-2027 Table 29: Neurovascular Stents Market in Japan: Historic Sales Analysis in US$ Thousand by Product Type for the Period 2012-2019 Table 30: Japanese Neurovascular Stents Market Share Analysis by Product Type: 2012 VS 2020 VS 2027 Table 31: Japanese Demand Estimates and Forecasts for Neurovascular Stents in US$ Thousand by End-Use: 2020 to 2027 Table 32: Japanese Neurovascular Stents Market in US$ Thousand by End-Use: 2012-2019 Table 33: Neurovascular Stents Market Share Shift in Japan by End-Use: 2012 VS 2020 VS 2027 CHINA Table 34: Chinese Neurovascular Stents Market Growth Prospects in US$ Thousand by Product Type for the Period 2020-2027 Table 35: Neurovascular Stents Historic Market Analysis in China in US$ Thousand by Product Type: 2012-2019 Table 36: Chinese Neurovascular Stents Market by Product Type: Percentage Breakdown of Sales for 2012, 2020, and 2027 Table 37: Chinese Demand for Neurovascular Stents in US$ Thousand by End-Use: 2020 to 2027 Table 38: Neurovascular Stents Market Review in China in US$ Thousand by End-Use: 2012-2019 Table 39: Chinese Neurovascular Stents Market Share Breakdown by End-Use: 2012 VS 2020 VS 2027 EUROPE Market Facts & Figures European Neurovascular Stents Market: Competitor Market Share Scenario (in %) for 2019 & 2025 Market Analytics Table 40: European Neurovascular Stents Market Demand Scenario in US$ Thousand by Region/Country: 2020-2027 Table 41: Neurovascular Stents Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2012-2019 Table 42: European Neurovascular Stents Market Share Shift by Region/Country: 2012 VS 2020 VS 2027 Table 43: European Neurovascular Stents Market Estimates and Forecasts in US$ Thousand by Product Type: 2020-2027 Table 44: Neurovascular Stents Market in Europe in US$ Thousand by Product Type: A Historic Review for the Period 2012-2019 Table 45: European Neurovascular Stents Market Share Breakdown by Product Type: 2012 VS 2020 VS 2027 Table 46: European Neurovascular Stents Addressable Market Opportunity in US$ Thousand by End-Use: 2020-2027 Table 47: Neurovascular Stents Market in Europe: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2012-2019 Table 48: European Neurovascular Stents Market Share Analysis by End-Use: 2012 VS 2020 VS 2027 FRANCE Table 49: Neurovascular Stents Market in France by Product Type: Estimates and Projections in US$ Thousand for the Period 2020-2027 Table 50: French Neurovascular Stents Historic Market Scenario in US$ Thousand by Product Type: 2012-2019 Table 51: French Neurovascular Stents Market Share Analysis by Product Type: 2012 VS 2020 VS 2027 Table 52: Neurovascular Stents Quantitative Demand Analysis in France in US$ Thousand by End-Use: 2020-2027 Table 53: French Neurovascular Stents Historic Market Review in US$ Thousand by End-Use: 2012-2019 Table 54: French Neurovascular Stents Market Share Analysis: A 17-Year Perspective by End-Use for 2012, 2020, and 2027 GERMANY Table 55: Neurovascular Stents Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Product Type for the Period 2020-2027 Table 56: German Neurovascular Stents Historic Market Analysis in US$ Thousand by Product Type: 2012-2019 Table 57: German Neurovascular Stents Market Share Breakdown by Product Type: 2012 VS 2020 VS 2027 Table 58: Neurovascular Stents Market in Germany: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2020-2027 Table 59: German Neurovascular Stents Market in Retrospect in US$ Thousand by End-Use: 2012-2019 Table 60: Neurovascular Stents Market Share Distribution in Germany by End-Use: 2012 VS 2020 VS 2027 ITALY Table 61: Italian Neurovascular Stents Market Growth Prospects in US$ Thousand by Product Type for the Period 2020-2027 Table 62: Neurovascular Stents Historic Market Analysis in Italy in US$ Thousand by Product Type: 2012-2019 Table 63: Italian Neurovascular Stents Market by Product Type: Percentage Breakdown of Sales for 2012, 2020, and 2027 Table 64: Italian Demand for Neurovascular Stents in US$ Thousand by End-Use: 2020 to 2027 Table 65: Neurovascular Stents Market Review in Italy in US$ Thousand by End-Use: 2012-2019 Table 66: Italian Neurovascular Stents Market Share Breakdown by End-Use: 2012 VS 2020 VS 2027 UNITED KINGDOM Table 67: United Kingdom Market for Neurovascular Stents: Annual Sales Estimates and Projections in US$ Thousand by Product Type for the Period 2020-2027 Table 68: Neurovascular Stents Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Product Type for the Period 2012-2019 Table 69: United Kingdom Neurovascular Stents Market Share Analysis by Product Type: 2012 VS 2020 VS 2027 Table 70: United Kingdom Demand Estimates and Forecasts for Neurovascular Stents in US$ Thousand by End-Use: 2020 to 2027 Table 71: United Kingdom Neurovascular Stents Market in US$ Thousand by End-Use: 2012-2019 Table 72: Neurovascular Stents Market Share Shift in the United Kingdom by End-Use: 2012 VS 2020 VS 2027 REST OF EUROPE Table 73: Rest of Europe Neurovascular Stents Market Estimates and Forecasts in US$ Thousand by Product Type: 2020-2027 Table 74: Neurovascular Stents Market in Rest of Europe in US$ Thousand by Product Type: A Historic Review for the Period 2012-2019 Table 75: Rest of Europe Neurovascular Stents Market Share Breakdown by Product Type: 2012 VS 2020 VS 2027 Table 76: Rest of Europe Neurovascular Stents Addressable Market Opportunity in US$ Thousand by End-Use: 2020-2027 Table 77: Neurovascular Stents Market in Rest of Europe: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2012-2019 Table 78: Rest of Europe Neurovascular Stents Market Share Analysis by End-Use: 2012 VS 2020 VS 2027 ASIA-PACIFIC Table 79: Neurovascular Stents Market in Asia-Pacific by Product Type: Estimates and Projections in US$ Thousand for the Period 2020-2027 Table 80: Asia-Pacific Neurovascular Stents Historic Market Scenario in US$ Thousand by Product Type: 2012-2019 Table 81: Asia-Pacific Neurovascular Stents Market Share Analysis by Product Type: 2012 VS 2020 VS 2027 Table 82: Neurovascular Stents Quantitative Demand Analysis in Asia-Pacific in US$ Thousand by End-Use: 2020-2027 Table 83: Asia-Pacific Neurovascular Stents Historic Market Review in US$ Thousand by End-Use: 2012-2019 Table 84: Asia-Pacific Neurovascular Stents Market Share Analysis: A 17-Year Perspective by End-Use for 2012, 2020, and 2027 REST OF WORLD Table 85: Rest of World Neurovascular Stents Market Estimates and Forecasts in US$ Thousand by Product Type: 2020 to 2027 Table 86: Rest of World Neurovascular Stents Historic Market Review by Product Type in US$ Thousand: 2012-2019 Table 87: Neurovascular Stents Market in Rest of World: Percentage Share Breakdown of Sales by Product Type for 2012, 2020, and 2027 Table 88: Rest of World Neurovascular Stents Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2020 to 2027 Table 89: Neurovascular Stents Market in Rest of World: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2012-2019 Table 90: Rest of World Neurovascular Stents Market Share Analysis by End-Use: 2012 VS 2020 VS 2027 IV. COMPETITION Total Companies Profiled: 42Read the full report: https://www.reportlinker.com/p05957507/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

  • Global Commercial Airlines Market 2020-2024: Market Analysis, Drivers, Restraints, Opportunities, and Threats - Technavio

    The Commercial Airlines Market will grow by USD 184.19 bn during 2020-2024